Drugs that contain Pomalidomide

1. Drug name - POMALYST

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8828427 CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Jun, 2031

(8 years from now)

CN102333525A CELGENE Formulation Of 4-Amino-2-(2,6-Dioxopiperidine-3-Yl)Isoindoline-1,3-Dione
Jan, 2017

(5 years ago)

EP3351240B1 CELGENE Formulations Of 4-Amino-2-(2,6-Dioxopiperidine-3-Yl)Isoindoline-1,3-Dione
May, 2030

(7 years from now)

EP2391355B1 CELGENE Formulations Of 4-Amino-2-(2,6-Dioxopiperidine-3-Yl)Isoindoline-1,3-Dione
May, 2030

(7 years from now)

EP3351240A1 CELGENE Formulations Of 4-Amino-2-(2,6-Dioxopiperidine-3-Yl)Isoindoline-1,3-Dione
May, 2030

(7 years from now)

EP2391355A2 CELGENE Formulations Of 4-Amino-2-(2,6-Dioxopiperidine-3-Yl)Isoindoline-1,3-Dione
May, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8673939 CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione May, 2023

(7 months from now)

US8735428 CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione May, 2023

(7 months from now)

US8735428

(Pediatric)

CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione Nov, 2023

(1 year, 1 month from now)

US8673939

(Pediatric)

CELGENE Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione Nov, 2023

(1 year, 1 month from now)

US8198262 CELGENE Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione Jun, 2025

(2 years from now)

US8198262

(Pediatric)

CELGENE Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione Dec, 2025

(3 years from now)

US9993467 CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione May, 2030

(7 years from now)

US10555939 CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione May, 2030

(7 years from now)

US9993467

(Pediatric)

CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione Nov, 2030

(8 years from now)

US10555939

(Pediatric)

CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione Nov, 2030

(8 years from now)

US8828427

(Pediatric)

CELGENE Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione Dec, 2031

(9 years from now)

Treatment: Use of pomalidomide for the treatment of multiple myeloma; use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy; Use of pomalidomide with dexamethasone for patients with multiple myeloma after at least two prior therapies including lenalidomide and a proteasome inhibitor and demonstrated disease progression on or within 60 days of completing the last therapy; use of pomalidomide for the treatment of multiple myeloma

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
1MG CAPSULE;ORAL Prescription
2MG CAPSULE;ORAL Prescription
3MG CAPSULE;ORAL Prescription
4MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.